고려대학교 의과대학 및 의과학연구지원센터 구성원이 아닌 경우에는 본인인증을 통하여 글을 작성할 수 있습니다.
- 본인인증 후 글을 작성할 수 있습니다.
내 명의의 휴대전화로 비밀번호를 재설정 할 수 있습니다.
A New Hope for Aggressive Meningioma
KU Medicine neurosurgeons discovered a new therapeutic target for meningioma progression
KU Medicine investigators found a clue to cure for a common brain tumor. A research team led by Drs. Shin-Hyuk Kang and Kyung-Jae Park, professors of neurosurgery, Korea University Anam Hospital together with Dr. Serk In Park, professor of biochemistry and molecular biology, performed laboratory experiments using patient samples, cancer cells growing on petri dishes and mice to pinpoint a molecule responsible for the progression of meningioma.
Meningioma is the most common primary brain tumor arising in the membrane of the brain. Most meningiomas have benign characteristics with favorable treatment outcomes, yet a fraction of the patients eventually recur with an aggressive type. Those recurrent meningiomas hardly responds to surgery, radiation therapy and chemotherapy, and the afflicted patients can only expect poor outcomes.
The KU Medicine research team examined 101 meningioma patient samples from Anam Hospital and found that a protein called FOXM1 plays important roles during the malignant conversion of meningioma. The team also showed that an experimental drug suppressing FOXM1 prevents meningioma growth in laboratory mice, confirming that FOXM1 is a crucial molecule for meningioma progression. Dr. Kang, the lead investigator, explained, “We are currently performing further research to develop a new drug targeting FOXM1, and also we are confirming whether we can use FOXM1 as a marker to predict which patients will ultimately progress to malignant meningiomas.”
This study entitled “Forkhead box M1 (FOXM1) transcription factor is a key oncogenic driver of aggressive human meningioma progression” was funded by the National Research Foundation of Korea and published on the June 9th 2019 issue of Neuropathology and Applied Neurobiology, one of the best among the top 10% of the neuro-science journals.
pubmed link: https://www.ncbi.nlm.nih.gov/pubmed/31179553
Neuropathol Appl Neurobiol. 2019 Jun 9. doi: 10.1111/nan.12571.
KU Medicine Steps Up its Competitive Edge through Active Exchange with Other Universities Abroad
KU College of Medicine will be on the forefront of setting the standards of medical education by having active cooperation and exchange with other schools abroad in academic affairs, clinical application and exchange of students and faculty.
Rapid, Economic and New ‘Molecular Diagnostic Technology’ Developed